• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Baird Medical Investment Holdings Ltd

    3/10/26 8:43:55 AM ET
    $BDMD
    Medical/Dental Instruments
    Health Care
    Get the next $BDMD alert in real time by email
    S-8 1 tm263761d1_s8.htm FORM S-8

     

    As filed with the Securities and Exchange Commission on March 10, 2026

     

    Registration No.

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM S-8

    REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933

     

    Baird Medical Investment Holdings Limited

    (Exact name of registrant as specified in its charter)

     

    Cayman Islands   Not Applicable
    (State or other jurisdiction of
    incorporation or organization)
     

    (I.R.S. Employer

    Identification No.)

     

    Room 202, 2/F, Baide Building, Building 11, No.15

    Rongtong Street, Yuexiu District, Guangzhou, Peoples Republic of China

    (86) 20 8218-5926

    (Address of Principal Executive Offices)

     

    2024 Equity Incentive Plan

    (Full title of the plan)

     

    Puglisi & Associates

    850 Library Avenue, Suite 204

    Newark, DE 19711

    (Name and address of agent for service)

     

    (302) 738-6680

    (Telephone number, including area code, of agent for service)

     

    Copies to:

    Dan Ouyang, Esq.

    K. Ronnie Li, Esq.

    Baker & McKenzie LLP

    Suite 3401, China World Office 2

    China World Trade Centre

    1 Jianguomenwai Dajie

    Beijing 100004

    People’s Republic of China

    (86-10) 6535-3800

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer ¨ Accelerated filer ¨
    Non-accelerated filer x Smaller reporting company ¨
    Emerging growth company x  

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ¨

     

     

     

     

     

     

    EXPLANATORY NOTE

     

    This Registration Statement is being filed by Baird Medical Investment Holdings Limited (the “Registrant”) to register additional Class A ordinary shares issuable pursuant to its 2024 Equity Incentive Plan (the “2024 Plan”) and consists of only those items required by General Instruction E to Form S-8. Pursuant to certain provisions of the 2024 Plan (referred to as the “evergreen provisions”), the number of ordinary shares that are available for award grant purposes under the 2024 Plan is automatically increased each year in accordance with a formula set forth in the 2024 Plan. Based on the above, the additional securities registered hereby consist of 1,229,381 Class A ordinary shares that were automatically added to the 2024 Plan, effective January 1, 2026, pursuant to the 2024 Plan’s evergreen provisions.

     

    In accordance with General Instruction E to Form S-8, the contents of the Registrant’s Registration Statement on Form S-8, filed on January 10, 2025, are incorporated herein by reference, except as otherwise set forth herein.

     

    1

     

     

    PART II

     

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

     

    Item 3. Incorporation of Documents by Reference.

     

    The Registrant is subject to the informational requirements of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) and, accordingly, files periodic reports and other information with the Commission. The Commission maintains a website that contains reports, proxy and information statements and other information regarding registrants that file electronically with the Commission, including the Registrant. The address for the Commission’s website is “http://www.sec.gov.” The following documents are incorporated by reference in this Registration Statement:

     

    (a) The Registrant’s Annual Report on Form 20-F for the fiscal year ended December 31, 2024 filed with the Commission on May 15, 2025;

     

    (b) The Registrant’s Current Reports on Form 6-K furnished to the Commission on December 5, 2025 and February 10, 2026; and

     

    (c) The description of the Registrant’s ordinary shares incorporated by reference in its registration statement on Form 8-A (File No. 001-42300) filed with the Commission under Section 12(b) of the Exchange Act on October 1, 2024, including any amendments or reports filed for the purpose of updating such description.

     

    Except to the extent such information is deemed furnished and not filed pursuant to securities laws and regulations, all documents subsequently filed by the Registrant pursuant to Sections 13(a), 13(c), 14, or 15(d) of the Exchange Act and, to the extent specifically designated therein, reports on Form 6-K furnished by the Registrant to the Commission, in each case, prior to the filing of a post-effective amendment to this Registration Statement indicating that all securities offered under this Registration Statement have been sold, or deregistering all securities then remaining unsold, shall be deemed to be incorporated by reference in this Registration Statement and to be a part hereof from the date of filing or furnishing of such documents.

     

    Any statement contained herein or in a document all or a portion of which is incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein or in any other subsequently filed document which also is or is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.

     

    Item 4. Description of Securities.

     

    Not applicable.

     

    Item 5. Interests of Named Experts and Counsel.

     

    None.

     

    II-1

     

     

    Item 6. Indemnification of Directors and Officers.

     

    Cayman Islands law does not limit the extent to which a company’s articles of association may provide for indemnification of officers and directors, except to the extent any such provision may be held by the Cayman Islands courts to be contrary to public policy, such as to provide indemnification against civil fraud or the consequences of committing a crime. The Registrant’s amended and restated memorandum and articles of association provide that the Registrant shall, subject to the limitations contained therein, indemnify each of its directors and officers (but not including its auditor) against all actions, proceedings, costs, charges, expenses, losses, damages or liabilities incurred or sustained by such directors or officer, other than by reason of such person’s dishonesty, willful default or fraud, in or about the conduct of the Registrant’s business or affairs (including as a result of any mistake of judgment) or in the execution or discharge of his or her duties, powers, authorities or discretions, including without prejudice to the generality of the foregoing, any costs, expenses, losses or liabilities incurred by such director or officer in defending (whether successfully or otherwise) any civil proceedings concerning the Registrant or its affairs in any court whether in the Cayman Islands or elsewhere.

     

    Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers or persons controlling the Registrant pursuant to the foregoing provisions, the Registrant has been informed that in the opinion of the Commission such indemnification is against public policy as expressed in the Securities Act and is therefore unenforceable.

     

    Item 7. Exemption from Registration Claimed.

     

    Not applicable.

     

    Item 8. Exhibits.

     

    EXHIBIT INDEX

     

    Exhibit   Description
    5.1 *   Opinion of Conyers Dill & Pearman
    10.1   Baird Medical Investment Holdings Limited 2024 Equity Incentive Plan (incorporated by reference to Exhibit 10.1 to the Registration Statement on Form S-8 (Reg. No. 333-284206), initially filed with the SEC on January 10, 2025)
    23.1 *   Consent of Kreit & Chiu CPA LLP
    23.2 *   Consent of Conyers Dill & Pearman (included as Exhibit 5.1)
    23.3 *   Consent of Marcum Asia CPAs LLP
    24.1 *   Power of Attorney (included on signature page hereof)
    107*   Filing Fee Table

     

      * Filed herewith.

     

    Item 9. Undertakings.

     

    (a) The undersigned registrant hereby undertakes:

     

    (1) To file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement:

     

    (i) To include any prospectus required by Section 10(a)(3) of the Securities Act of 1933;

     

    (ii) To reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than 20 percent change in the maximum aggregate offering price set forth in the “Calculation of Registration Fee” table in the effective registration statement.

     

    (iii) To include any material information with respect to the plan of distribution not previously disclosed in the registration statement or any material change to such information in the registration statement.

     

    II-2

     

     

    provided, however, that paragraphs (a)(1)(i), (a)(1)(ii) and (a)(1)(iii) of this section do not apply if the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the Securities and Exchange Commission by the registrant pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 that are incorporated by reference in the registration statement, or is contained in a form of prospectus filed pursuant to Rule 424(b).

     

    (2) That, for the purpose of determining any liability under the Securities Act of 1933, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

     

    (3) To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.

     

    (4) That, for the purpose of determining liability under the Securities Act of 1933 to any purchaser:

     

    (i) Each prospectus filed by the registrant pursuant to Rule 424(b)(3) shall be deemed to be part of the registration statement as of the date the filed prospectus was deemed part of and included in the registration statement; and

     

    (ii) Each prospectus required to be filed pursuant to Rule 424(b)(2), (b)(5), or (b)(7) as part of a registration statement in reliance on Rule 430B relating to an offering made pursuant to Rule 415(a)(1)(i), (vii), or (x) for the purpose of providing the information required by Section 10(a) of the Securities Act of 1933 shall be deemed to be part of and included in the registration statement as of the earlier of the date such form of prospectus is first used after effectiveness or the date of the first contract of sale of securities in the offering described in the prospectus. As provided in Rule 430B, for liability purposes of the issuer and any person that is at that date an underwriter, such date shall be deemed to be a new effective date of the registration statement relating to the securities in the registration statement to which that prospectus relates, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof. Provided, however, that no statement made in a registration statement or prospectus that is part of the registration statement or made in a document incorporated or deemed incorporated by reference into the registration statement or prospectus that is part of the registration statement will, as to a purchaser with a time of contract of sale prior to such effective date, supersede or modify any statement that was made in the registration statement or prospectus that was part of the registration statement or made in any such document immediately prior to such effective date.

     

    (5) That, for the purpose of determining liability of the registrant under the Securities Act of 1933 to any purchaser in the initial distribution of the securities: The undersigned registrant undertakes that in a primary offering of securities of the undersigned registrant pursuant to this registration statement, regardless of the underwriting method used to sell the securities to the purchaser, if the securities are offered or sold to such purchaser by means of any of the following communications, the undersigned registrant will be a seller to the purchaser and will be considered to offer or sell such securities to such purchaser:

     

    (i) Any preliminary prospectus or prospectus of the undersigned registrant relating to the offering required to be filed pursuant to Rule 424;

     

    (ii) Any free writing prospectus relating to the offering prepared by or on behalf of the undersigned registrant or used or referred to by the undersigned registrant;

     

    (iii) The portion of any other free writing prospectus relating to the offering containing material information about the undersigned registrant or its securities provided by or on behalf of the undersigned registrant; and

     

    (iv) Any other communication that is an offer in the offering made by the undersigned registrant to the purchaser.

     

    (b) That, for purposes of determining any liability under the Securities Act of 1933, each filing of the registrant’s annual report pursuant to section 13(a) or section 15(d) of the Securities Exchange Act of 1934 (and, where applicable, each filing of an employee benefit plan’s annual report pursuant to section 15(d) of the Securities Exchange Act of 1934) that is incorporated by reference in the registration statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

     

    (c) Insofar as indemnification for liabilities arising under the Securities Act of 1933 may be permitted to directors, officers and controlling persons of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the Securities and Exchange Commission such indemnification is against public policy as expressed in the Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Act and will be governed by the final adjudication of such issue.

     

    II-3

     

     

    Signatures

     

    Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the Guangzhou, PRC, on March 10, 2026.

     

    Baird Medical Investment Holdings Limited
       
    By: /s/ Haimei Wu  
      Haimei Wu  
      Director and Chief Executive Officer  
      (principal executive officer)  

     

    POWER OF ATTORNEY

     

    Each person whose signature appears below hereby appoints Haimei Wu his or her true and lawful attorney-in-fact with full power of substitution or re-substitution, for such person and in such person’s name, place and stead, in any and all capacities, to sign on such person’s behalf, individually and in each capacity stated below, any and all amendments, including post-effective amendments to this Registration Statement, and to sign any and all additional registration statements relating to the same offering of securities of the Registration Statement that are filed pursuant to Rule 462 of the Securities Act of 1933, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact, full power and authority to do and perform each and every act and thing requisite or necessary to be done in and about the premises, as fully to all intents and purposes as such person might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact, or their substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

     

    Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed by the following persons in the capacities and on the dates indicated.

     

     

    Signature   Title   Date
             
    /s/ Haimei Wu   Director and Chief Executive Officer   March 10, 2026
    Name: Haimei Wu   (Principal Executive Officer)    
             
    /s/ Jie Li   Acting Chief Financial Officer   March 10, 2026
    Name: Jie Li    (Principal Financial and Accounting Officer)    
             
    /s/ Wei Hou   Director   March 10, 2026
    Name: Wei Hou        
             
    /s/ Quan Qiu   Director   March 10, 2026
    Name: Quan Qiu        
             
    /s/ Joseph Douglas Ragan III   Independent Director   March 10, 2026
    Name: Joseph Douglas Ragan III        
             
    /s/ Michael Mingzhao Xing   Independent Director   March 10, 2026
    Name: Michael Mingzhao Xing        
             
    /s/ Lijian Xu   Independent Director   March 10, 2026
    Name: Lijian Xu        
             
    /s/ Gabrielle Bilciu-Wolfson   Independent Director   March 10, 2026
    Name: Gabrielle Bilciu-Wolfson        

     

    II-4

     

     

    SIGNATURE OF AUTHORIZED REPRESENTATIVE IN THE UNITED STATES

     

    Pursuant to the Securities Act of 1933 as amended, the undersigned, the duly authorized representative in the United States of America of the Registrant, has signed this registration statement thereto in New York, NY on March 10, 2026.

     

    Puglisi & Associates

    Authorized U.S. Representative

     
         
    By: /s/ Donald J. Puglisi  
    Name: Donald J. Puglisi  
    Title: Managing Director  

     

    II-5

     

    Get the next $BDMD alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BDMD

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $BDMD
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Baird Medical Accelerates U.S. Expansion in Interventional Thyroidology at NASIT 2026

    NEW YORK, March 9, 2026 /PRNewswire/ -- Baird Medical Investment Holdings Ltd. (NASDAQ:BDMD) ("Baird Medical" or the "Company"), a market leader in minimally invasive Microwave Ablation (MWA) technology, today announced its successful strategic showcase at the 2026 North American Society for Interventional Thyroidology (NASIT) in Portland, Oregon. This engagement advances the Company's goal to expand patient access to advanced, minimally invasive treatment options. Baird Medical's proprietary MWA platforms garnered significant interest during the event's thermal ablation worksho

    3/9/26 8:30:00 AM ET
    $BDMD
    Medical/Dental Instruments
    Health Care

    Baird Medical Accelerates Global Registration of AI-Driven Surgical Software

    NEW YORK, March 4, 2026 /PRNewswire/ -- Baird Medical Investment Holdings Ltd. (NASDAQ:BDMD) ("Baird Medical"), a market leader in minimally invasive Microwave Ablation (MWA) technology, today announced the successful completion of development for its cross-platform surgical software, officially commencing the registration process in the United States, the European Union, and China. Leveraging a proprietary artificial intelligence model, the system automates core clinical workflows, including anatomical mapping, dynamic treatment planning, and procedural simulations. By integrat

    3/4/26 8:30:00 AM ET
    $BDMD
    Medical/Dental Instruments
    Health Care

    Baird Medical Accelerates U.S. Expansion at NASOIE 2026

    NEW YORK, March 2, 2026 /PRNewswire/ -- Baird Medical Investment Holdings Ltd. (NASDAQ:BDMD) ("Baird Medical" or the "Company"), a market leader in minimally invasive Microwave Ablation (MWA) technology, today announced its participation at the 2026 North American Society of Interventional Endocrinologists (NASOIE) Annual Meeting in Miami, Florida. Building on successful engagements at previous NASOIE gatherings, this initiative reinforces the Company's enduring commitment to physician education and advances its strategy to expand patient access to minimally invasive therapies.

    3/2/26 8:30:00 AM ET
    $BDMD
    Medical/Dental Instruments
    Health Care

    $BDMD
    SEC Filings

    View All

    SEC Form S-8 filed by Baird Medical Investment Holdings Ltd

    S-8 - Baird Medical Investment Holdings Ltd (0001982444) (Filer)

    3/10/26 8:43:55 AM ET
    $BDMD
    Medical/Dental Instruments
    Health Care

    SEC Form 6-K filed by Baird Medical Investment Holdings Ltd

    6-K - Baird Medical Investment Holdings Ltd (0001982444) (Filer)

    2/10/26 7:59:47 AM ET
    $BDMD
    Medical/Dental Instruments
    Health Care

    SEC Form 424B3 filed by Baird Medical Investment Holdings Ltd

    424B3 - Baird Medical Investment Holdings Ltd (0001982444) (Filer)

    1/16/26 4:32:46 PM ET
    $BDMD
    Medical/Dental Instruments
    Health Care

    $BDMD
    Leadership Updates

    Live Leadership Updates

    View All

    Baird Medical Appoints Mark Saxton as U.S. CEO; Taps Veteran from NeuroPace, Smith + Nephew, and Covidien to Lead Commercial Expansion

    NEW YORK, Dec. 3, 2025 /PRNewswire/ -- Baird Medical Investment Holdings Ltd. (NASDAQ:BDMD) ("Baird Medical" or the "Company"), a market leader in minimally invasive Microwave Ablation (MWA) technology, today announced the appointment of Mark Saxton as Chief Executive Officer of its U.S. subsidiary. Mr. Saxton is a seasoned medical device executive with more than 25 years of commercial leadership experience, including a decade advancing intravascular RF ablation technologies. He will lead all U.S. operations, including sales, marketing, and market development, as Baird Medical

    12/3/25 8:30:00 AM ET
    $BDMD
    Medical/Dental Instruments
    Health Care

    Baird Medical Champions Global Collaboration in Microwave Ablation at International Thyroid Workshop

    NEW YORK, Oct. 20, 2025 /PRNewswire/ -- Baird Medical Investment Holdings Ltd. (NASDAQ:BDMD), a global leader in minimally invasive Microwave Ablation (MWA) technology, today announced its participation in the 3rd International Workshop on Thermal Ablation of Thyroid Tumor and Hyperparathyroidism. The prestigious academic event was hosted by the China-Japan Friendship Hospital in Beijing, China, from October 17-18, 2025. Chaired by Prof. Ming'an Yu, a leading authority in interventional medicine, the workshop served as a vital platform for the world's foremost experts to share

    10/20/25 8:30:00 AM ET
    $BDMD
    Medical/Dental Instruments
    Health Care